Bioactivity and molecular targets of novel substituted quinolines in murine and human tumor cell lines in vitro

International Journal of Oncology

Volumn 36, Issue 3, 2010, Pages 673-688

  Perchellet, Elisabeth M ^a   Crow, Kyle R ^a   Gakhar, Gunjan ^a   Nguyen, Thu Annelise ^a   Shi, Aibin ^a   Hua, Duy H ^a   Perchellet, Jean Pierre H ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Caspases; DNA interaction and fragmentation; Human epidermal growth factor receptors; Ki 67 expression; Macromolecule syntheses; Mitotic and binucleated cells; Nucleoside transport; Poly(ADP ribose) polymerase 1; Synthetic quinolines; Tumor cell proliferation

Indexed keywords

ADENOSINE; CASPASE 2; CASPASE 3; DNA; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETHIDIUM BROMIDE; GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; KI 67 ANTIGEN; LEUCINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; QUINOLINE DERIVATIVE; RADICICOL; RNA; SUCCINIC ACID; TANESPIMYCIN; THYMIDINE; URIDINE; 3-(4'-ACETOXY-3',5'-DIMETHOXY)BENZYLIDENE-1,2-DIHYDROPYRROLO(2,1-B)QUINAZOLINE-9-ONE; EPIDERMAL GROWTH FACTOR; ETHIDIUM; NUCLEOSIDE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BREAST TUMOR; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL METABOLISM; CELL PROLIFERATION; CHROMOSOME DAMAGE; CONTROLLED STUDY; CYTOKINESIS; CYTOTOXICITY; DNA FRAGMENTATION; DOWN REGULATION; DRUG INHIBITION; DRUG TARGETING; EPIDERMOID TUMOR; FLUORESCENCE; GAP JUNCTION; HUMAN; HUMAN CELL; IMMUNODETECTION; IN VITRO STUDY; LEUKEMIA; MACROMOLECULE; MICRONUCLEUS; MITOSIS; MONOLAYER CULTURE; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNTHESIS; WESTERN BLOTTING; ANIMAL; CHEMISTRY; METABOLISM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; EPIDERMAL GROWTH FACTOR; ETHIDIUM; GAP JUNCTIONS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; NUCLEOSIDES; PYRROLES; QUINAZOLINES; QUINOLINES; SIGNAL TRANSDUCTION;

EID: 77149142874     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000543     Document Type: Article

References (43)

1. Shi A, Nguyen TA, Battina SK, Rana S, Takemoto DJ, Chiang PK and Hua DH: Synthesis and anti-breast cancer activities of substituted quinolines. Bioorg Med Chem Lett 18: 3364-3368, 2008.
2. Gakhar G, Ohira T, Shi A, Hua DH and Nguyen TA: Antitumor effect of substituted quinolines in breast cancer cells. Drug Dev Res 69: 526-534, 2008.
3. Musil LS, Le AC, van Slyke JK and Roberts LM: Regulation of connexin degradation as a mechanism to increase gap junction. J Biol Chem 275: 25207-25215, 2000.
4. Martin PE and Evans WH: Incorporation of connexins into plasma membranes and gap junctions. Cardiovasc Res 62: 378-387, 2004.
5. Ruch RJ: The role of gap junctional intercellular communication in neoplasia. Ann Clin Lab Sci 24: 216-231, 1994.
6. Zhang ZQ, Lin ZX and Lu YY: Studies on the reduction of malignant phenotypes in a highly metastatic human lung carcinoma - correlated changes of intercellular communication, cytoskeletons, oncogenes and antioncogenes. Zhonghua Zhong Liu Za Zhi (Chin J Oncol) 16: 88-92, 1994.
7. Na HK, Wilson MR, Kang KS, Chang CC, Grunberger D and Trosko JE: Restoration of gap junctional intercellular communication by caffeic acid phenethyl ester (CAPE) in a ras-transformed rat liver epithelial cell line. Cancer Lett 157: 31-38, 2000.
8. Holder JW, Elmore E and Barrett JC: Gap junction function and cancer. Cancer Res 53: 3475-3485, 1993.
9. Dubina MV, Iatckii NA, Popov DE, Vasil'ev SV and Krutovskikh VA: Connexin 43, but not connexin 32, is mutated at advanced stages of human sporadic colon cancer. Oncogene 21: 4992-4996, 2002.
10. Eghbali B, Kessler JA, Reid LM, Roy C and Spray DC: Involvement of gap junctions in tumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc Natl Acad Sci USA 88: 10701-10705, 1991.
11. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
12. Lauer WMRC, Arnold RT, Drake NL, Hook JV and Tinker J: Some derivatives of 8-aminoquinoline. J Am Chem Soc 68: 1546-1548, 1946.
13. LaMontagne MP, Blumberg P and Strube RE: Antimalarials. 14. 5-(Aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents. J Med Chem 25: 1094-1097, 1982.
14. Cory AH, Owen JC, Barltrop JA and Cory JG: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212, 1991.
15. Perchellet EM, Magill MJ, Huang X, Dalke DM, Hua DH and Perchellet J-P: 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro. Anticancer Drugs 11: 339-352, 2000.
16. Perchellet EM, Ward MM, Skaltsounis A-L, Kostakis IK, Pouli N, Marakos P and Perchellet J-P: Antiproliferative and proapoptotic activities of pyranoxanthenones, pyranothioxanthenones and their pyrazole-fused derivatives in HL-60 cells. Anticancer Res 26: 2791-2804, 2006.
17. Morgan AR, Lee JS, Pulleyblank DS, Murray NL and Evans DH: Ethidium fluorescence assays. Part 1. Physico-chemical studies. Nucleic Acids Res 7: 547-569, 1979.
18. Perchellet EM, Wang Y, Weber RL, Sperfslage BJ, Lou K, Crossland J, Hua DH and Perchellet J-P: Synthetic 1,4-anthracenedione analogs induce cytochrome c release, caspase-9, -3, and -8 activities, poly(ADP-ribose) polymerase-1 cleavage and internucleosomal DNA fragmentation in HL-60 cells by a mechanism which involves caspase-2 activation but not Fas signaling. Biochem Pharmacol 67: 523-537, 2004.
19. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S and Zeiger E: HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 534: 65-75, 2003.
20. Wang Y, Perchellet EM, Tamura M, Hua DH and Perchellet J-P: Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines. Cancer Lett 188: 73-83, 2002.
21. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J and Palombella VJ: Design, synthesis and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, watersoluble inhibitors of Hsp90. J Med Chem 49: 4606-4615, 2006.
22. Lieu C-H, Chang Y-N and Lai Y-K: Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60 cells. Biochem Pharmacol 53: 1587-1596, 1997.
23. Duriez PJ and Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75: 337-349, 1997.
24. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
25. Isaacs JS, Xu W and Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213-217, 2003.
26. Kamal A, Boehm MF and Burrows FJ: Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 10: 283-290, 2004.
27. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW and Pearl LH: Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42: 260-266, 1999.
28. Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
29. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM and Lackey K: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61: 7196-7203, 2001.
30. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou H-R, Wang Y-F and Wissner A: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64: 3958-3965, 2004.
31. Perchellet EM, Magill MJ, Huang X, Brantis CE, Hua DH and Perchellet JP: Triptycenes: a novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range in vitro. Anticancer Drugs 10: 749-766, 1999.
32. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
33. Shi Q and King RW: Chromosome non-disjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 437: 1038-1042, 2005.
34. Nagata S: Apoptotic DNA fragmentation. Exp Cell Res 256: 12-18, 2000.
35. Herceg Z and Wang ZQ: Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 477: 97-110, 2001.
36. Perchellet EM, Wang Y, Weber RL, Lou K, Hua DH and Perchellet J-P: Antitumor triptycene bisquinones induce a caspase-independent release of mitochondrial cytochrome c and a caspase-2-mediated activation of initiator caspase-8 and -9 in HL-60 cells by a mechanism which does not involve Fas signaling. Anticancer Drugs 15: 929-946, 2004.
37. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
38. Wang Y, Perchellet EM, Ward MM, Lou K, Zhao H, Battina SK, Wiredu B, Hua DH and Perchellet JP: Antitumor triptycene analogs induce a rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria. Int J Oncol 28: 161-172, 2006.
39. Perchellet EM, Wang Y, Lou K, Zhao H, Battina SK, Hua DH and Perchellet JP: Antitumor triptycene analogs directly interact with isolated mitochondria to rapidly trigger markers of permeability transition. Anticancer Res 27: 3259-3272, 2007.
40. Walter L, Miyoshi H, Leverve X, Bernardi P and Fontaine E: Regulation of the mitochondrial permeability transition pore by ubiquinone analogs. A progress report. Free Radic Res 36: 405-412, 2002.
41. + depletion and mitochondrial permeability transition. J Biol Chem 279: 18895-18902, 2004.
42. Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772, 2005.
43. Zhang H and Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82: 488-499, 2004.